Tilavonemab  (Synonyms: ABBV-8E12; C2N-8E12)

Tilavonemab (ABBV-8E12) is a humanized anti-tau antibody that targets the extracellular form of pathological tau protein aggregates by binding to the N-terminal 25-30 amino acid residues of tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates, reduces the loss of brain volume, slows the progression of tau pathology, and improves cognitive abilities in transgenic mice expressing mutant human tau. Tilavonemab is used in Alzheimer's disease research^[1][2][3].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Chimeric

tau^[1].

2096513-89-0

Liquid

Colorless to light yellow

[Tilavonemab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized Human Tau Protein (His Tag) can bind Tilavonemab. The EC₅₀ for this effect is 2.182 ng/mL.

• [1]. Vaswani P A, et al. Immunotherapy in progressive supranuclear palsy. Curr Opin Neurol. 2020 Aug;33(4):527-533.  [Content Brief]

  [2]. Lopez-Cuina M, et al. Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders[J]. Revue Neurologique, 2022, 178(5): 460-471.  [Content Brief]

  [3]. Neațu M, et al. Monoclonal antibody therapy in Alzheimer’s disease[J]. Pharmaceutics, 2023, 16(1): 60.  [Content Brief]